Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. Grade 3-4 adverse events were more common in the nivolumab group, however, there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Merkel cell carcinoma (MCC), an aggressive skin cancer, poses a clinical
Neoadjuvant Nivolumab Eastern Cooperative Oncology Group Rating Level Resectable Lung Between Oct Dermatologic Malignancy
Source: 2minutemedicine.com